These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 12154207)

  • 1. The effects of disease-modifying anti-rheumatic drugs on the Health Assessment Questionnaire score. Lessons from the leflunomide clinical trials database.
    Scott DL; Strand V
    Rheumatology (Oxford); 2002 Aug; 41(8):899-909. PubMed ID: 12154207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group.
    Tugwell P; Wells G; Strand V; Maetzel A; Bombardier C; Crawford B; Dorrier C; Thompson A
    Arthritis Rheum; 2000 Mar; 43(3):506-14. PubMed ID: 10728742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis.
    Strand V; Scott DL; Emery P; Kalden JR; Smolen JS; Cannon GW; Tugwell P; Crawford B;
    J Rheumatol; 2005 Apr; 32(4):590-601. PubMed ID: 15801012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leflunomide improves quality of life in rheumatoid arthritis.
    Scott DL
    Scand J Rheumatol Suppl; 1999; 112():23-9. PubMed ID: 10668524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group.
    Strand V; Tugwell P; Bombardier C; Maetzel A; Crawford B; Dorrier C; Thompson A; Wells G
    Arthritis Rheum; 1999 Sep; 42(9):1870-8. PubMed ID: 10513801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leflunomide in monotherapy of rheumatoid arthritis: meta-analysis of randomized trials.
    Golicki D; Newada M; Lis J; Pol K; Hermanowski T; Tłustochowicz M
    Pol Arch Med Wewn; 2012; 122(1-2):22-32. PubMed ID: 22353705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine.
    Scott DL; Smolen JS; Kalden JR; van de Putte LB; Larsen A; Kvien TK; Schattenkirchner M; Nash P; Oed C; Loew-Friedrich I;
    Ann Rheum Dis; 2001 Oct; 60(10):913-23. PubMed ID: 11557646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved functional ability in patients with rheumatoid arthritis--longterm treatment with leflunomide versus sulfasalazine. European Leflunomide Study Group.
    Kalden JR; Scott DL; Smolen JS; Schattenkirchner M; Rozman B; Williams BD; Kvien TK; Jones P; Williams RB; Oed C; Rosenburg R;
    J Rheumatol; 2001 Sep; 28(9):1983-91. PubMed ID: 11550964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease modification in rheumatoid arthritis with leflunomide.
    Emery P
    Scand J Rheumatol Suppl; 1999; 112():9-14. PubMed ID: 10668522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort.
    Lukas C; Mary J; Debandt M; Daïen C; Morel J; Cantagrel A; Fautrel B; Combe B
    Arthritis Res Ther; 2019 Nov; 21(1):243. PubMed ID: 31730497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leflunomide, a novel immunomodulator for the treatment of active rheumatoid arthritis.
    Goldenberg MM
    Clin Ther; 1999 Nov; 21(11):1837-52; discussion 1821. PubMed ID: 10890256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group.
    Strand V; Cohen S; Schiff M; Weaver A; Fleischmann R; Cannon G; Fox R; Moreland L; Olsen N; Furst D; Caldwell J; Kaine J; Sharp J; Hurley F; Loew-Friedrich I
    Arch Intern Med; 1999 Nov; 159(21):2542-50. PubMed ID: 10573044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting.
    Alten R; Burkhardt H; Feist E; Krüger K; Rech J; Rubbert-Roth A; Voll RE; Elbez Y; Rauch C
    Arthritis Res Ther; 2018 Jan; 20(1):1. PubMed ID: 29329602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial.
    Pincus T; Strand V; Koch G; Amara I; Crawford B; Wolfe F; Cohen S; Felson D
    Arthritis Rheum; 2003 Mar; 48(3):625-30. PubMed ID: 12632413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year followup study.
    Kalden JR; Schattenkirchner M; Sörensen H; Emery P; Deighton C; Rozman B; Breedveld F
    Arthritis Rheum; 2003 Jun; 48(6):1513-20. PubMed ID: 12794818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of the new DMARD leflunomide: comparison to placebo and sulfasalazine in active rheumatoid arthritis.
    Smolen JS
    Scand J Rheumatol Suppl; 1999; 112():15-21. PubMed ID: 10668523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A simplified disease activity index for rheumatoid arthritis for use in clinical practice.
    Smolen JS; Breedveld FC; Schiff MH; Kalden JR; Emery P; Eberl G; van Riel PL; Tugwell P
    Rheumatology (Oxford); 2003 Feb; 42(2):244-57. PubMed ID: 12595618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial.
    Kremer JM; Genovese MC; Cannon GW; Caldwell JR; Cush JJ; Furst DE; Luggen ME; Keystone E; Weisman MH; Bensen WM; Kaine JL; Ruderman EM; Coleman P; Curtis DL; Kopp EJ; Kantor SM; Waltuck J; Lindsley HB; Markenson JA; Strand V; Crawford B; Fernando I; Simpson K; Bathon JM
    Ann Intern Med; 2002 Nov; 137(9):726-33. PubMed ID: 12416946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.
    Verschueren P; De Cock D; Corluy L; Joos R; Langenaken C; Taelman V; Raeman F; Ravelingien I; Vandevyvere K; Lenaerts J; Geens E; Geusens P; Vanhoof J; Durnez A; Remans J; Vander Cruyssen B; Van Essche E; Sileghem A; De Brabanter G; Joly J; Meyfroidt S; Van der Elst K; Westhovens R
    Ann Rheum Dis; 2015 Jan; 74(1):27-34. PubMed ID: 25359382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
    Cohen S; Cannon GW; Schiff M; Weaver A; Fox R; Olsen N; Furst D; Sharp J; Moreland L; Caldwell J; Kaine J; Strand V
    Arthritis Rheum; 2001 Sep; 44(9):1984-92. PubMed ID: 11592358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.